Over the past four years, private equity (PE) firms that invested in life science assets have faced a difficult reality. While many investors still debate whether some sectors of the market are in a ...

Azenta, Inc. stock trades near $20 with a 0.5x sales valuation and $600M net cash. Click for this updated look at AZTA and ...

W hile challenges persist in the short term, there are signs pointing toward long-term growth for life sciences, according to JLL’s 2024 Life Sciences Real Estate Perspective and Cluster Analysis. The ...

A surge of 147% in a single session is an unusual occurrence in biotech — and nearly unprecedented for a company that has spent years trading discreetly under the radar. However, that is precisely ...

Taking a position in a life science exchange-traded fund (ETF) provides exposure to a basket of stocks focused on the healthcare sector, while mitigating the risks of holding shares in a single ...